Comparative immunogenecity of foot and mouth disease virus antigens in FMD-haemorrhagic septicaemia combined vaccine and FMD vaccine alone in buffalo calves.
Humoral immune response was evaluated by monitoring the serum antibody titres and virus specific IgM titres against Foot and Mouth Disease (FMD) virus antigens in serum samples obtained from different groups of calves inoculated with combined vaccine or FMD vaccine alone, on 0, 7, 14, 21, 28, 42 and 56 days post-vaccination (DPV). The cellular immune response was monitored by MTT based lymphoproliferation in peripheral blood mononuclear cell cultures. Higher liquid phase blocking (LPB) ELISA antibody titres were observed in calves receiving combined vaccine as compared to calves immunized with FMD vaccine alone with the peak titres in both the groups obtained on 21 days post-vaccination. However, the virus specific IgM titres were significantly higher in group of calves inoculated with combined vaccine than FMD vaccine alone. The lymphoproliferative responses against FMDV types O, A22 and Asia 1 in the groups receiving combined vaccine and FMD vaccine alone started increasing gradually after day 14 and reached peak levels on 28 DPV followed by a gradual decline subsequently. The group receiving combined vaccine showed higher proliferative responses on in vitro stimulation with FMD virus type O, whereas, with FMD virus type Asia 1, the responses were significantly higher on 14 and 21 DPV as compared to the group immunized with FMD vaccine alone. However, in the group receiving combined vaccine, the responses on in vitro stimulation with FMD virus type A22 were significantly higher than FMD vaccine alone group on all DPV except on 42 DPV.
Chhabra
Rajesh
R
Regional Research Center on FMD, Department of Veterinary Microbiology, CCS Haryana Agricultural University, Hisar 125 004, India. somu@hau.nic.in
Sharma
R
R
Kakker
N K
NK
D000818:Animals; D000917:Antibody Formation; D000956:Antigens, Viral / Q000276:immunology*; D002020:Buffaloes; D002455:Cell Division; D004396:Coloring Agents / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005536:Foot-and-Mouth Disease / Q000517:prevention & control / Q000821:virology; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology*; D006483:Hemorrhagic Septicemia / Q000378:metabolism*; D007111:Immunity, Cellular; D007075:Immunoglobulin M / Q000737:chemistry; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D013778:Tetrazolium Salts / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D013997:Time Factors; D014612:Vaccines
D000956:Antigens, Viral; D004396:Coloring Agents; D007075:Immunoglobulin M; D013778:Tetrazolium Salts; D013844:Thiazoles; D014612:Vaccines; C022616:thiazolyl blue